Amylyx Pharmaceuticals, Inc. (AMLX) Tops Q3 EPS by 1c

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) reported Q3 EPS of ($0.92), $0.01 better than the analyst estimate of ($0.93). Revenue for the quarter came in at $350 thousand versus the consensus estimate of $1.42 million.

For earnings history and earnings-related data on Amylyx Pharmaceuticals, Inc. (AMLX) click here.

You May Also Be Interested In

• FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• Worthington Industries (WOR) Misses Q4 EPS by 9c